NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis $7.42 -0.24 (-3.13%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$7.41 -0.01 (-0.13%) As of 07/25/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GlucoTrack Stock (NASDAQ:GCTK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GlucoTrack alerts:Sign Up Key Stats Today's Range$7.17▼$7.9150-Day Range$5.22▼$9.6052-Week Range$5.11▼$3,756.00Volume75,991 shsAverage Volume1.48 million shsMarket Capitalization$3.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey. Read More GlucoTrack Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreGCTK MarketRank™: GlucoTrack scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for GlucoTrack. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GlucoTrack is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlucoTrack is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted34.47% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently increased by 695.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlucoTrack does not currently pay a dividend.Dividend GrowthGlucoTrack does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted34.47% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently increased by 695.51%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment1.35 News SentimentGlucoTrack has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GlucoTrack this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for GCTK on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlucoTrack insiders have not sold or bought any company stock.Percentage Held by Insiders12.91% of the stock of GlucoTrack is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.92% of the stock of GlucoTrack is held by institutions.Read more about GlucoTrack's insider trading history. Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Email Address GCTK Stock News HeadlinesGlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s WhyJuly 21, 2025 | msn.comGlucotrack, Inc. Successfully Repurchases Over 90% of Series A Warrants as Part of Capital Formation Strategy - NasdaqJuly 10, 2025 | nasdaq.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 26 at 2:00 AM | Timothy Sykes (Ad)Glucotrack Announces Repurchase of Series A WarrantsJuly 8, 2025 | globenewswire.comGlucotrack reports positive results from first human trial of blood glucose monitor - Investing.comJune 26, 2025 | investing.comGlucotrack's Investigational Cont. Glucose Monitor Shows Accuracy In First-In-Human Study - NasdaqJune 26, 2025 | nasdaq.comGlucoTrack Inc trading resumesJune 25, 2025 | msn.comWhy Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?June 25, 2025 | benzinga.comSee More Headlines GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed this year? GlucoTrack's stock was trading at $447.60 on January 1st, 2025. Since then, GCTK shares have decreased by 98.3% and is now trading at $7.42. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($20.40) earnings per share (EPS) for the quarter. When did GlucoTrack's stock split? Shares of GlucoTrack reverse split on Tuesday, February 4th 2025.The 1-20 reverse split was announced on Thursday, January 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GlucoTrack own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlucoTrack investors own include Rolls-Royce Holdings PLC (RYCEY), Blink Charging (BLNK), Cameco (CCJ), Cybin (CYBN), Cyclo Therapeutics (CYTH), Ford Motor (F) and iShares U.S. Infrastructure ETF (IFRA). Company Calendar Last Earnings5/14/2025Today7/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:GCTK CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($56.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.60 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-544.87% Debt Debt-to-Equity Ratio0.03 Current Ratio4.85 Quick Ratio4.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($983.43) per share Price / Book-0.01Miscellaneous Outstanding Shares480,000Free Float415,000Market Cap$3.56 million OptionableNot Optionable Beta-0.24 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:GCTK) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.